Cyclophosphamide, doxorubicin, and gemcitabine combination chemotherapy for treatment of metastatic and locally advanced breast cancer.
Metastatic and locally advanced breast cancer remain a fertile field for investigation of new chemotherapeutic agents and chemotherapy combinations. We administered combination chemotherapy with cyclophosphamide, doxorubicin, and gemcitabine to 20 women with metastatic and/or locally advanced breast cancer. The regimen was well tolerated, although it required granulocyte colony stimulating factor (G-CSF) support. This novel regimen resulted in a complete response rate of 20% and overall response rates of 89% (intent-to-treat response of 80%). Gemcitabine is a highly effective agent that warrants farther evaluation as a component of multidrug chemotherapy.